223 related articles for article (PubMed ID: 20839898)
1. Dalfampridine extended release: in multiple sclerosis.
Chwieduk CM; Keating GM
CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
4. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
5. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
Blight AR; Henney HR; Cohen R
Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
[TBL] [Abstract][Full Text] [Related]
6. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
7. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
[TBL] [Abstract][Full Text] [Related]
8. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
[TBL] [Abstract][Full Text] [Related]
9. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
[TBL] [Abstract][Full Text] [Related]
10. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
Pikoulas TE; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
[TBL] [Abstract][Full Text] [Related]
11. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
Coleman CI; Sobieraj DM; Marinucci LN
Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
[TBL] [Abstract][Full Text] [Related]
12. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
13. Dalfampridine in multiple sclerosis.
Goodman AD; Hyland M
Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
[TBL] [Abstract][Full Text] [Related]
14. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Cohen JA; Cameron MH; Goldman MD; Goodman AD; Miller AE; Rollins A; Llorens L; Patni R; Elfont R; Johnson R
Mult Scler; 2022 Apr; 28(5):817-830. PubMed ID: 34449295
[TBL] [Abstract][Full Text] [Related]
16. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
Lugaresi A
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
[TBL] [Abstract][Full Text] [Related]
18. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
[TBL] [Abstract][Full Text] [Related]
19. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
Hobart J; Blight AR; Goodman A; Lynn F; Putzki N
Neurology; 2013 Apr; 80(16):1509-17. PubMed ID: 23535489
[TBL] [Abstract][Full Text] [Related]
20. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
Fernandez O; Berger T; Hartung HP; Putzki N
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
